-
1 month ago | 
nature.com | Oren Pasvolsky |Lei Feng |James Davis |Aimaz Afrough |Mariola Vazquez-Martinez |Utkarsh Goel | +22 more
AbstractTeclistamab, a BCMA-directed bispecific antibody, received regulatory approval for relapsed/refractory multiple myeloma (RRMM) based on the MajesTEC-1 study. Despite the fact that myeloma is primarily a cancer of elderly adults, only 15% of MajesTEC-1 participants (n = 24) were ≥75 years old. In this multicenter retrospective study, we report real-world outcomes of a large cohort of older RRMM patients treated with teclistamab.
-
1 month ago | 
nature.com | Aqeeb ur Rehman |Moazzam Shahzad |Faiz Anwer |Joseph McGuirk |Mohamad Mohty |Nausheen Ahmed | +1 more
AbstractMeasurable residual disease (MRD) testing is emerging as a crucial prognostic and treatment-guiding tool in multiple myeloma (MM). Despite its potential, routine clinical adoption remains inconsistent. This study aimed to explore oncologists’ perspectives on MRD testing and identify barriers and facilitators to its clinical integration. A cross-sectional, modified Delphi survey was conducted among hematologists and oncologists globally, and 115 responses were received.
-
Dec 4, 2024 | 
nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more
AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
-
Dec 4, 2024 | nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more
AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
-
Dec 2, 2024 | 
nature.com | Joseph McGuirk |Leland Metheny III |Mark Litzow |Scott Rowley |Roni Tamari |Hillard M. Lazarus
Correction to: Bone Marrow Transplantation https://doi.org/10.1038/s41409-023-02068-3, published online 08 August 2023Following the publication of this article, the authors would like to add an additional reference as below to add context on the original discovery of PLX-R18's proposed therapeutic capabilities:16. Gaberman E, Pinzur L, Levdansky L, Tsirlin M, Nete~ N, Aberman Z, et al.
-
Sep 6, 2024 | 
digitalcommons.library.tmc.edu | Christopher J. Ferreri |Hamza Hashmi |Leyla O. Shune |Joseph McGuirk
AbstractMost patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients treated with sequential BCMA-TT are limited. We analyzed clinical outcomes for patients infused with standard-of-care idecabtagene vicleucel, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, at 11 US medical centers.
-
May 30, 2024 | 
nature.com | Danai Dima |James Davis |Hussein Awada |Faiz Anwer |Shahzad Raza |Zahra Mahmoudjafari | +2 more
AbstractThe presence of extramedullary disease (EMD) has been associated with poor outcomes in patients with relapsed-refractory multiple myeloma (RRMM). Herein, we report the outcomes of RRMM patients who were treated with standard-of-care (SOC) chimeric antigen receptor (CAR) T-cell therapy and had active extraosseous EMD before the infusion. Data were retrospectively collected from patients at three US institutions with the intent to receive SOC CAR T.
-
Apr 11, 2024 | 
nature.com | Aimaz Afrough |Doris Hansen |Surbhi Sidana |Lauren C. Peres |Danai Dima |Joseph McGuirk | +6 more
Idecabtagene vicleucel (ide-cel) the first FDA-approved gene therapy for relapsed refractory multiple myeloma (RRMM). However, its administration presents challenges in logistical management, selecting bridging therapy (BT), and customizing T-cell manufacturing, a complex process spanning several weeks [1]. In the KarMMa trial, BT was allowed but limited to specific prior drug classes (e.g., dexamethasone, cyclophosphamide (Cy), daratumumab, carfilzomib, bortezomib, or pomalidomide) [2].
-
Dec 12, 2023 | 
newsbreak.com | Joseph McGuirk
By signing up for our newsletter, you agree to our Terms of Use and Privacy Policy
-
Dec 12, 2023 | 
onclive.com | Joseph McGuirk
Video synopsis is AI-generated and reviewed by OncLive editorial staff. The field of cancer immunotherapy is witnessing significant innovations, particularly in the treatment of non-Hodgkin lymphomas, including diffuse large B-cell lymphoma (DLBCL). One major challenge is the time it takes to manufacture CAR T-cell therapies, which can range from a month to a month and a half.
